https://orcid.org/0000-0002-1846-2946
Abstract
Bitter taste receptors (T2Rs) consist of 25 functional receptors that can be found in various types of cells throughout the human body with responses ranging from detecting bitter taste to suppressing pathogen-induced inflammation upon activation. Numerous studies have observed clinical associations with genetic or phenotypic variants in bitter taste receptors, most notably that of the receptor isoform T2R38. With genetic variants playing a role in the response of the body to bacterial quorum-sensing molecules, bacterial metabolites, medicinal agonists and nutrients, we examine how T2R polymorphisms, expression levels and bitter taste perception can lead to varying clinical associations. From these genetic and phenotypic differences, healthcare management can potentially be individualized through appropriately administering drugs with bitter masking to increase compliance; optimizing nutritional strategies and diets; avoiding the use of T2R agonists if this pathway is already activated from bacterial infections; adjusting drug regimens based on differing prognoses; or adjusting drug regimens based on T2R expression levels in the target cell type and bodily region.
Abbreviations
AHL, acyl-homoserine lactone; AVI, alanine-valine-isoleucine; COVID-19, coronavirus disease 2019; CRS, chronic rhinosinusitis; CT, computed tomography; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; PAV, proline-alanine-valine; PROP, 6-n-propylthiouracil; PTC, phenylthiocarbamide; SNP, single nucleotide polymorphism; T2R, bitter taste receptor; TAS2R, bitter taste receptor gene.
Disclosure
Dr Weyland Cheng reports grants from Henan Provincial Medical Science and Technology Research Plan Joint Construction Project, during the conduct of the study. The authors report no conflicts of interest in this work.